Jonathan Wessen

First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [⁶⁸Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma

Michael S. Hofman, Ben Tran, Darren R. Feldman et al. · Journal of Nuclear Medicine · 2024 · 62 citations · Full text

Medicine, Nuclear Medicine, Oncology +15

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial

Éric Pujade-Lauraine, Jessica Brown, Alan Barnicle et al. · JCO Precision Oncology · 2023 · 58 citations · Full text

Life Sciences, Genetics, Oncology +17

Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with <i>EGFR</i>-mutant, <i>MET</i>-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

Helena A. Yu, Myung‐Ju Ahn, Sang‐We Kim et al. · Cancer Research · 2019 · 21 citations

Medicine, Oncology, Pharmacology +15

Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with <i>EGFR</i>-mutant, <i>MET</i>-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

Lecia V. Sequist, Jong Seok Lee, Ji‐Youn Han et al. · Cancer Research · 2019 · 18 citations

Medicine, Oncology, Pharmacology +14

Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data

Laurence Albigès, Daniel Y.C. Heng, Jae‐Lyun Lee et al. · European Journal of Cancer · 2022 · 14 citations · Full text

Medicine, Oncology, Pharmacology +15